Neuropace, Inc. NPCE R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Neuropace, Inc.’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s r&d credit carryforward?
- Neuropace, Inc. (NPCE) reported r&d credit carryforward of $16.81M in Q4 2025.
- How has Neuropace, Inc.'s r&d credit carryforward changed year-over-year?
- Neuropace, Inc.'s r&d credit carryforward increased by 12.8% year-over-year, from $14.9M to $16.81M.
- What is the long-term trend for Neuropace, Inc.'s r&d credit carryforward?
- Over 5 years (2020 to 2025), Neuropace, Inc.'s r&d credit carryforward has grown at a 10.2% compound annual growth rate (CAGR), from $10.33M to $16.81M.
- What does r&d credit carryforward mean?
- This metric quantifies the value of research and development tax credits that have been earned but not yet utilized to offset future tax liabilities. It represents a potential future cash flow benefit for the company as it moves toward profitability. Monitoring this balance helps investors understand the company's ability to reduce future tax burdens through historical innovation investments.